Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Fludarabine may be of benefit to prevent rejection of grafted solid organs in children during chemo-immunotherapy treatment for post transplant lymphoproliferative diseases (PTLDs).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: A.O. Ospedale Papa Giovanni XXIII
• Treatments: Cyclophosphamide; Doxorubicin; Fludarabine; Fludarabine phosphate; Liposomal doxorubicin; Rituximab; Vidarabine

Criteria

Inclusion Criteria:

• Children less 18 years old and

• Non Burkitt, CD20 positive aggressive PTLD and

• Solid organ transplant

Exclusion Criteria:

• Burkitt PTLD